These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28764731)

  • 1. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model.
    Idigoras I; Arrospide A; Portillo I; Arana-Arri E; Martínez-Indart L; Mar J; de Koning HJ; Lastra R; Soto-Gordoa M; van der Meulen M; Lansdorp-Vogelaar I
    BMC Public Health; 2017 Aug; 18(1):78. PubMed ID: 28764731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.
    Arrospide A; Idigoras I; Mar J; de Koning H; van der Meulen M; Soto-Gordoa M; Martinez-Llorente JM; Portillo I; Arana-Arri E; Ibarrondo O; Lansdorp-Vogelaar I
    BMC Cancer; 2018 Apr; 18(1):464. PubMed ID: 29695234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates.
    Zorzi M; Zappa M;
    Gut; 2020 Feb; 69(2):311-316. PubMed ID: 31040168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study.
    Buskermolen M; Cenin DR; Helsingen LM; Guyatt G; Vandvik PO; Haug U; Bretthauer M; Lansdorp-Vogelaar I
    BMJ; 2019 Oct; 367():l5383. PubMed ID: 31578177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.
    Buskermolen M; Gini A; Naber SK; Toes-Zoutendijk E; de Koning HJ; Lansdorp-Vogelaar I
    Med Decis Making; 2018 Nov; 38(8):917-929. PubMed ID: 30343626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lesions detected in a colorectal cancer screening program in the Basque Country: first round (2009-2011)].
    Portillo I; Idígoras I; Ojembarrena E; Arana E; Luis Hurtado J; Basurko R; Tapia M; Luz Peña M
    Gastroenterol Hepatol; 2013 May; 36(5):301-8. PubMed ID: 23618538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years.
    Idigoras Rubio I; Arana-Arri E; Portillo Villares I; Bilbao Iturribarrria I; Martínez-Indart L; Imaz-Ayo N; de la Cruz M; de Castro V; López de Munain A; Torrejón Perez I; Gutiérrez-Ibarluzea I
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):197-204. PubMed ID: 30543575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colon Cancer Screening - Is It Time Yet?
    Bhurgri H; Samiullah S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia.
    Naber SK; Almadi MA; Guyatt G; Xie F; Lansdorp-Vogelaar I
    Saudi J Gastroenterol; 2021; 27(4):208-216. PubMed ID: 33835054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.
    Meester RG; Zauber AG; Doubeni CA; Jensen CD; Quinn VP; Helfand M; Dominitz JA; Levin TR; Corley DA; Lansdorp-Vogelaar I
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1445-1451.e8. PubMed ID: 27211498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.
    Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I
    Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
    Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
    Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estimated impact of the current colorectal screening program in France].
    Barré S; Leleu H; Vimont A; Kaufmanis A; Gendre I; Taleb S; De Bels F
    Rev Epidemiol Sante Publique; 2020 Jun; 68(3):171-177. PubMed ID: 32417153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Participation and yield of a population-based colorectal cancer screening programme in China.
    Chen H; Li N; Ren J; Feng X; Lyu Z; Wei L; Li X; Guo L; Zheng Z; Zou S; Zhang Y; Li J; Zhang K; Chen W; Dai M; He J;
    Gut; 2019 Aug; 68(8):1450-1457. PubMed ID: 30377193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.
    Zorzi M; Fedeli U; Schievano E; Bovo E; Guzzinati S; Baracco S; Fedato C; Saugo M; Dei Tos AP
    Gut; 2015 May; 64(5):784-90. PubMed ID: 25179811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors related to the participation and detection of lesions in colorectal cancer screening programme-based faecal immunochemical test.
    Portillo I; Arana-Arri E; Gutiérrez-Ibarluzea I; Bilbao I; Luis Hurtado J; Sarasqueta C; Idigoras I; Bujanda L;
    Eur J Public Health; 2018 Dec; 28(6):1143-1148. PubMed ID: 29982586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain).
    Portillo I; Arana-Arri E; Idigoras I; Bilbao I; Martínez-Indart L; Bujanda L; Gutierrez-Ibarluzea I
    World J Gastroenterol; 2017 Apr; 23(15):2731-2742. PubMed ID: 28487610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.